title: Overexpressed or intraperitoneally injected human transferrin prevents photoreceptor degeneration in rd10 mice.
abstract: OBJECTIVE
  Retinal degeneration has been associated with iron accumulation in age-related macular degeneration (AMD), and in several rodent models that had one or several iron regulating protein impairments. We investigated the iron concentration and the protective role of human transferrin (hTf) in rd10 mice, a model of retinal degeneration.
  
  
  METHODS
  The proton-induced X-ray emission (PIXE) method was used to quantify iron in rd10 mice 2, 3, and 4 weeks after birth. We generated mice with the β-phosphodiesterase mutation and hTf expression by crossbreeding rd10 mice with TghTf mice (rd10/hTf mice). The photoreceptor loss and apoptosis were evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling in 3-week-old rd10/hTf mice and compared with 3-week-old rd10 mice. The neuroprotective effect of hTf was analyzed in 5-day-old rd10 mice treated by intraperitoneal administration with hTf for up to 25 days. The retinal hTf concentrations and the thickness of the outer nuclear layer were quantified in all treated mice at 25 days postnatally.
  
  
  RESULTS
  PIXE analysis demonstrated an age-dependent iron accumulation in the photoreceptors of rd10 mice. The rd10/hTf mice had the rd10 mutation, expressed high levels of hTf, and showed a significant decrease in photoreceptor death. In addition, rd10 mice intraperitoneally treated with hTf resulted in the retinal presence of hTf and a dose-dependent reduction in photoreceptor degeneration.
  
  
  CONCLUSIONS
  Our results suggest that iron accumulation in the retinas of rd10 mutant mice is associated with photoreceptor degeneration. For the first time, the enhanced survival of cones and rods in the retina of this model has been demonstrated through overexpression or systemic administration of hTf. This study highlights the therapeutic potential of Tf to inhibit iron-induced photoreceptor cell death observed in degenerative diseases such as retinitis pigmentosa and age-related macular degeneration.
authors.affiliation: Inserm, Paris, France. picardemilie@gmail.com
authors.forename: Emilie
authors.initials: E
authors.lastname: Picard
authors.forename: Laurent
authors.initials: L
authors.lastname: Jonet
authors.forename: Claire
authors.initials: C
authors.lastname: Sergeant
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Vesvres
authors.forename: Francine
authors.initials: F
authors.lastname: Behar-Cohen
authors.forename: Yves
authors.initials: Y
authors.lastname: Courtois
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Jeanny
mesh_terms: D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D004195:Disease Models, Animal; D004577:Electron Probe Microanalysis; D006801:Humans; D007274:Injections, Intraperitoneal; D007501:Iron / Q000378:metabolism; D051379:Mice; D012160:Retina / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D017949:Retinal Cone Photoreceptor Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D012162:Retinal Degeneration / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D017948:Retinal Rod Photoreceptor Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D013052:Spectrometry, X-Ray Emission; D014168:Transferrin / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D014168:Transferrin; D007501:Iron